Neurolief Inc., a medical device company focused on neuromodulation therapies for neuropsychiatric conditions, today ...

The FDA approved a prescription at-home brain neuromodulation therapy as an adjunctive depression treatment for adults, maker ...

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under physician oversight.

The FDA has approved ProlivRx, the first prescription, home-based brain neuromodulation therapy, as an adjunctive treatment ...

Neurolief announced today that the FDA granted approval for its Proliv Rx at-home neuromodulation therapy for treating ...

At Stanford, a treatment that aims magnetic pulses at the brain is showing results for people with treatment-resistant ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

The clinical trial is expected to enroll up to 40 patients in two stages: an initial open-label pilot (10 patients) followed by a randomized, double-blinded, sham-controlled trial (30 patients).

Financing led by Genesys Capital with participation from Cleveland Clinic and JobsOhio Ventures -- Genesys Capital Managing Partner Jamie Stiff to join Enspire Board of Directors -- Proceeds to ...

Significant improvement in depressive symptoms among patients using Proliv™Rx compared to sham controls. Favorable safety profile with minimal adverse events. High patient adherence and satisfaction ...

Auricular vagal neuromodulation therapy is a non-invasive and non-surgical treatment that could aid cardiovascular disease ...

Data presented at CTAD showed strong separation from placebo and statistical significance in mild-to-moderate patients on key global, cognitive, and behavioral measures including CDR-SB, ADAS- Cog 11 ...